CAD 0.1
(0.0%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 250.41 Thousand CAD | -67.2% |
2022 | 763.47 Thousand CAD | 47.04% |
2021 | 519.22 Thousand CAD | 10.02% |
2020 | 471.93 Thousand CAD | -19.61% |
2019 | 587.03 Thousand CAD | 80.93% |
2018 | 324.45 Thousand CAD | 140.06% |
2017 | 135.15 Thousand CAD | -36.76% |
2016 | 213.71 Thousand CAD | 235.36% |
2015 | 63.72 Thousand CAD | 144.77% |
2014 | 26.03 Thousand CAD | 0.0% |
2013 | - CAD | 0.0% |
2012 | - CAD | 0.0% |
2011 | - CAD | 0.0% |
2010 | - CAD | 0.0% |
2009 | - CAD | 0.0% |
2008 | - CAD | 0.0% |
2007 | - CAD | 0.0% |
2006 | - CAD | 0.0% |
2005 | - CAD | -100.0% |
2004 | 5800.00 CAD | 0.0% |
2003 | - CAD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q1 | 242.81 Thousand CAD | -3.04% |
2024 Q2 | 727.65 Thousand CAD | 199.68% |
2023 Q4 | 250.41 Thousand CAD | -66.86% |
2023 Q1 | 798.25 Thousand CAD | 4.56% |
2023 Q2 | 865.24 Thousand CAD | 8.39% |
2023 FY | 250.41 Thousand CAD | -67.2% |
2023 Q3 | 755.52 Thousand CAD | -12.68% |
2022 Q2 | 576.27 Thousand CAD | 16.71% |
2022 Q1 | 493.75 Thousand CAD | -4.91% |
2022 Q4 | 763.47 Thousand CAD | 16.5% |
2022 FY | 763.47 Thousand CAD | 47.04% |
2022 Q3 | 655.34 Thousand CAD | 13.72% |
2021 Q3 | 458.09 Thousand CAD | -15.84% |
2021 Q1 | 454.78 Thousand CAD | -3.63% |
2021 FY | 519.22 Thousand CAD | 10.02% |
2021 Q2 | 544.31 Thousand CAD | 19.69% |
2021 Q4 | 519.22 Thousand CAD | 13.35% |
2020 Q3 | 443.27 Thousand CAD | -15.02% |
2020 FY | 471.93 Thousand CAD | -19.61% |
2020 Q2 | 521.63 Thousand CAD | -5.01% |
2020 Q4 | 471.93 Thousand CAD | 6.47% |
2020 Q1 | 549.13 Thousand CAD | -6.46% |
2019 Q3 | 535.91 Thousand CAD | 22.65% |
2019 FY | 587.03 Thousand CAD | 80.93% |
2019 Q4 | 587.03 Thousand CAD | 9.54% |
2019 Q1 | 308.24 Thousand CAD | -5.0% |
2019 Q2 | 436.94 Thousand CAD | 41.75% |
2018 Q3 | 130.4 Thousand CAD | 7.53% |
2018 Q2 | 121.27 Thousand CAD | -7.6% |
2018 Q4 | 324.45 Thousand CAD | 148.82% |
2018 FY | 324.45 Thousand CAD | 140.06% |
2018 Q1 | 131.25 Thousand CAD | -2.89% |
2017 FY | 135.15 Thousand CAD | -36.76% |
2017 Q2 | 166 Thousand CAD | -13.07% |
2017 Q4 | 135.15 Thousand CAD | -17.19% |
2017 Q3 | 163.21 Thousand CAD | -1.68% |
2017 Q1 | 190.95 Thousand CAD | -10.65% |
2016 Q1 | 138.11 Thousand CAD | 116.74% |
2016 FY | 213.71 Thousand CAD | 235.36% |
2016 Q4 | 213.71 Thousand CAD | 14.54% |
2016 Q3 | 186.58 Thousand CAD | 32.53% |
2016 Q2 | 140.79 Thousand CAD | 1.94% |
2015 Q1 | 60.44 Thousand CAD | 132.18% |
2015 FY | 63.72 Thousand CAD | 144.77% |
2015 Q3 | 81.17 Thousand CAD | 5.07% |
2015 Q4 | 63.72 Thousand CAD | -21.49% |
2015 Q2 | 77.25 Thousand CAD | 27.81% |
2014 Q3 | 25.86 Thousand CAD | 0.0% |
2014 FY | 26.03 Thousand CAD | 0.0% |
2014 Q1 | - CAD | 0.0% |
2014 Q2 | - CAD | 0.0% |
2014 Q4 | 26.03 Thousand CAD | 0.68% |
2013 Q1 | - CAD | 0.0% |
2013 Q4 | - CAD | 0.0% |
2013 Q2 | - CAD | 0.0% |
2013 FY | - CAD | 0.0% |
2013 Q3 | - CAD | 0.0% |
2012 Q4 | - CAD | 0.0% |
2012 FY | - CAD | 0.0% |
2012 Q1 | - CAD | 0.0% |
2012 Q2 | - CAD | 0.0% |
2012 Q3 | - CAD | 0.0% |
2011 Q1 | - CAD | 0.0% |
2011 FY | - CAD | 0.0% |
2011 Q2 | - CAD | 0.0% |
2011 Q3 | - CAD | 0.0% |
2011 Q4 | - CAD | 0.0% |
2010 Q4 | - CAD | 0.0% |
2010 FY | - CAD | 0.0% |
2010 Q3 | - CAD | 0.0% |
2010 Q2 | - CAD | 0.0% |
2010 Q1 | - CAD | 0.0% |
2009 Q1 | - CAD | 0.0% |
2009 FY | - CAD | 0.0% |
2009 Q4 | - CAD | 0.0% |
2009 Q3 | - CAD | 0.0% |
2009 Q2 | - CAD | 0.0% |
2008 FY | - CAD | 0.0% |
2008 Q4 | - CAD | 0.0% |
2008 Q3 | - CAD | 0.0% |
2008 Q1 | - CAD | 0.0% |
2008 Q2 | - CAD | 0.0% |
2007 Q4 | - CAD | 0.0% |
2007 Q2 | - CAD | 0.0% |
2007 Q1 | - CAD | 0.0% |
2007 FY | - CAD | 0.0% |
2007 Q3 | - CAD | 0.0% |
2006 Q3 | - CAD | 0.0% |
2006 Q4 | - CAD | 0.0% |
2006 Q2 | - CAD | 0.0% |
2006 Q1 | - CAD | 0.0% |
2006 FY | - CAD | 0.0% |
2005 Q2 | 71.29 Thousand CAD | 0.0% |
2005 FY | - CAD | -100.0% |
2005 Q1 | - CAD | -100.0% |
2005 Q3 | 23.94 Thousand CAD | -66.41% |
2005 Q4 | - CAD | -100.0% |
2004 FY | 5800.00 CAD | 0.0% |
2004 Q1 | - CAD | 0.0% |
2004 Q2 | - CAD | 0.0% |
2004 Q3 | - CAD | 0.0% |
2004 Q4 | 5800.00 CAD | 0.0% |
2003 Q2 | - CAD | 0.0% |
2003 Q3 | - CAD | 0.0% |
2003 Q4 | - CAD | 0.0% |
2003 FY | - CAD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
Arch Biopartners Inc. | - CAD | -Infinity% |
Covalon Technologies Ltd. | 5.94 Million CAD | 95.787% |
Hemostemix Inc. | - CAD | -Infinity% |
Universal Ibogaine Inc. | - CAD | -Infinity% |
MedMira Inc. | 182.42 Thousand CAD | -37.272% |
Marvel Biosciences Corp. | - CAD | -Infinity% |
NervGen Pharma Corp. | - CAD | -Infinity% |
XORTX Therapeutics Inc. | - CAD | -Infinity% |